Previous 10 | Next 10 |
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Kinnate Biopharma Inc. (KNTE) is expected to report $-0.69 for Q3 2023
2023-09-19 08:25:16 ET Losers: Rocket Lab USA ( RKLB ) -24% after launch failure leads to a loss of payload. Digital Transformation Opportunities Corp. ( DTOC ) -23% . Terran Orbital Corporation ( LLAP ) -18% prices $32.5M stock offering . E...
2023-09-18 19:28:41 ET More on Kinnate Biopharma Seeking Alpha’s Quant Rating on Kinnate Biopharma Historical earnings data for Kinnate Biopharma Financial information for Kinnate Biopharma Kinnate Biopharma: More A Bet Than An Investment At This Early...
Promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 selective progr...
2023-09-03 05:26:58 ET Summary Kinnate Biopharma is a precision oncology biotech with a unique approach to targeted therapy, but faces challenges in financing and cash burn. The company's pipeline includes a drug called exarafenib, which has shown promise in targeting various muta...
2023-08-08 17:57:31 ET Kinnate Biopharma press release ( NASDAQ: KNTE ): Q2 GAAP EPS of -$0.68 beats by $0.08 . As of June 30, 2023, total cash, cash equivalents and investments were $204.3 million, which is expected to fund current operations into early 2025. Fo...
Received FDA clearance of IND application for brain-penetrant MEK inhibitor, KIN-7136; expect to enter the clinic with Phase 1 trial in the second half of 2023 Cash, cash equivalents and investments of $204.3 million as of June 30, 2023 anticipated to fund operations into early 2025 ...
2023-06-22 17:31:01 ET Gainers: Trupanion ( TRUP ) +15% . Stronghold Digital Mining ( SDIG ) +6% . Pinduoduo ( PDD ) +6% . CareMax ( CMAX ) +5% . Seer ( SEER ) +4% . Losers: Kinnate Biopharma ( KNTE ) -5% . Ca...
2023-06-11 09:51:51 ET Summary Shares of precision oncology concern Kinnate Biopharma Inc. (KNTE) have crashed 93% from their all-time high as long overdue data from a Phase 1 study failed to impress. The company is advancing a couple of early-stage compounds but has hit some bump...
News, Short Squeeze, Breakout and More Instantly...
Kinnate Biopharma Inc. Company Name:
KNTE Stock Symbol:
NASDAQ Market:
Kinnate Biopharma Inc. Website:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced th...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...